摘要
目的:观察瑞舒伐他汀对阵发性房颤(AF)患者心房肌电生理重构的影响。方法:将入选的56例持续性AF患者分为瑞舒伐他汀加胺碘酮、美托洛尔组(观察组)和胺碘酮加美托洛尔组(对照组)。对患者行药物复律或电复律后,利用食管心房调搏测定心房有效不应期(AERP),观察用药前后AERP的变化。结果:观察组的AERP在处理前后分别为(197.5714±11.84330)ms和(238.4286±17.08222)ms,AERP增长20.68%;对照组的AERP在处理前后分别为(198.5000±12.96000)ms和(212.5000±12.22073)ms,AERP增长0.705%。采用重复测量方差分析,两组的差异有统计学意义,P<0.05。结论:瑞舒伐他汀联合胺碘酮和美托洛尔缓释片有明显的协同作用,能够延长心房有效不应期。
Obsjective ：To investigate the effect of rosuvastatain on atrial electrical remodelling of the patients with persistant atrial fibrillation.Methods： 56 patients with persistant atrial fibrillation were randomly divided into observation group （rosuvastatain,amiodarone and metoprolol） and control group（amiodarone and metoprolol）.Pharmacological and eletrical cardioversions were used on the patients at first, and then the atrial effective refractory period（AERP） was measured and evaluated by transesophageal atrial pacing technology before and after having the drugs.Results：The observation group＇s AERP before and after the arrangement respectively was （197.5714±11.84330）ms and （238.4286±17.08222）ms,while the control group was （198.5000±12.96000）ms and （212.5000±12.22073）ms.Using the repetitive measure variance analysis,the two groups had significant statistical difference （P=0.011）.Conclusion： Rosuvastatain,amiodarone and metoprolol have obvious synergetic effect, and they can lengthen the atrium effective refractory period.
出处
《现代医药卫生》
2010年第6期807-808,共2页
Journal of Modern Medicine & Health
关键词
心房颤动
电重构
有效不应期
瑞舒伐他汀
Atrial fiberillation
Electrical remodeling
Atrial effective refractory period
Rosuvastatain
